Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of Protection

1 Mar 2001

Abstract excerpt

The antibody data supporting the use of meningococcal serogroup C conjugate (MCC) vaccines in the United Kingdom were generated by serum bactericidal assay (SBA) using rabbit complement (rSBA). This may give higher titers than those obtained with human complement (hSBA), for which the "gold standard" correlate of protection for meningococcal C disease is a titer of > or =4. Comparison of rSBA and hSBA titers in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Infections and Vaccines
Share to Pneumonia and Respiratory Infections
Share to Virology and Viral Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 11179328
DOI: 10.1128/iai.69.3.1568-1573.2001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of ProtectionPMID 11179328Read ↗

Long-term protection in children with meningococcal C conjugate vaccination: lessons learnedSemantic proximity Read ↗

Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectivenessSemantic proximity Read ↗

Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster doseSemantic proximity Read ↗

Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenBSemantic proximity Read ↗

Influence of Prior Meningococcal C Polysaccharide Vaccination on the Response and Generation of Memory after Meningococcal C Conjugate Vaccination in Young ChildrenSemantic proximity Read ↗

Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of LifeSemantic proximity Read ↗

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverageSemantic proximity Read ↗

Complement‐Dependent Synergistic Bactericidal Activity of Antibodies against Factor H–Binding Protein, a Sparsely Distributed Meningococcal Vaccine AntigenSemantic proximity Read ↗

Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian ToddlersSemantic proximity Read ↗

Immunogenicity of a Meningococcal B Vaccine during a University OutbreakSemantic proximity Read ↗

Safety and Immunogenicity of a Serogroups A/C Neisseria meningitidis Oligosaccharide—Protein Conjugate Vaccine in Young ChildrenSemantic proximity Read ↗

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in AfricansSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.